摘要
目的探讨老年持续性心房颤动患者应用华法林抗凝治疗的有效性、安全性及国际标准化比值(INR)范围.方法老年持续性心房颤动患者服用华法林抗凝治疗69例,观察华法林达标时间、维持剂量、安全的INR范围及不良反应.结果华法林达标时间及维持剂量虽有个体差异,但多数(88%)患者在15～30 d内以1.5～2.25 mg/d的量使INR稳定于1.8～2.5,出血发生率最低.结论老年持续性心房颤动患者应用华法林抗凝治疗时,使INR稳定于1.8～2.5既有效又安全.
Objective To explore the efficacy,safety and range of international normalized ratio（INR） of warfarin in the treatment of elderly persistent atrial fibrillation. Methods There were 69 elderly patients with persistent atrial fibrillation,who were treated with warfarin. Its aim-time, dosage, range of INR, and side-effect were observed. Results There was difference in the aim-time of warfarin and dosage indlvidually,but INR could be maintained to 1.8-2.5 in 88% patients with warfarin（ 1.5-2.25 mg/d） in 15-30 days. Bleeding incidence was the lowest. Conclusion Warfarin for the treatment of elderly persistent atrial fibrillation is both efficient and safe when INR can be maintained between 1. 8-2.5.
出处
《中国综合临床》
北大核心
2005年第11期973-974,共2页
Clinical Medicine of China
